Industry expert sees combination drugs as new growth engine

Published: 2009-11-26 07:00:00

Updated: 2009-11-26 07:00:00

Combination products will turn out to be tremendously lucrative as one of strategic items once they receive formal approval from a reliable drug-licensing agency and are put onto the market, according to a local market analyst.

“Combination drugs accounts for 28.5 percent of overall pharmaceut...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK